Izzyring (Ethinylestradiol, Etonogestrel)

Ethinylestradiol activates estrogen receptors while etonogestrel activates progesterone receptors. Together they suppress the hypothalamic‑pituitary‑ovarian axis, lowering luteinizing hormone and follicle‑stimulating hormone release, which prevents follicular development and ovulation. The progestogenic effect also thickens cervical mucus and modifies the endometrium, creating an environment hostile to fertilisation and implantation.

The prescribed regimen for Izzyring is determined by the treating clinician. Typically, a single vaginal ring is inserted and left in place for three consecutive weeks, followed by a ring‑free week to allow for withdrawal bleeding. Exact dosing and timing should follow the prescriber’s instructions and local product labeling.

Izzyring is contraindicated in women who are pregnant or suspect they might be pregnant. Because it delivers systemic hormones, it is generally not recommended for use while breastfeeding; the hormones may pass into breast milk and affect the infant. Women should discuss alternative contraception options with their healthcare provider if they are pregnant or nursing.

To order Izzyring, submit an enquiry on the product page at gnhindia.com specifying the required quantity. GNH India supplies hospitals, pharmacies and procurement teams across international markets. After the request, the sales team will verify trade or institutional credentials, then respond with pricing, availability, shipping details (including any cold‑chain requirements) and the necessary import documentation.

The primary alternative to Izzyring is the combined oral contraceptive pill. While both deliver ethinylestradiol and a progestogen, the vaginal ring provides continuous hormone release for three weeks with a single insertion, eliminating daily pill taking and reducing gastrointestinal absorption variability. Oral pills require daily adherence, whereas the ring offers a more convenient, low‑maintenance option for many users.

Izzyring should be stored at ambient temperature, preferably below 25 °C, in its original packaging. Protect the product from excess moisture, direct sunlight and extreme heat. Do not freeze the ring. Keep it out of reach of children and handle it with clean, dry hands to maintain sterility before insertion.

Izzyring is a flexible vaginal ring that the user inserts into the vagina, where it remains in place for three weeks. After three weeks, the ring is removed and discarded, and a ring‑free week follows to allow withdrawal bleeding. A new ring is then inserted to start the next cycle. Insertion and removal can be performed by the user after appropriate instruction.

The most serious risks include thromboembolic events such as deep‑vein thrombosis or pulmonary embolism, cerebrovascular accidents (stroke or transient ischemic attack), myocardial infarction, and severe allergic reactions including anaphylaxis. These events are rare but require immediate medical attention. Women with a history of clotting disorders or cardiovascular disease should be evaluated carefully before use.

Izzyring is contraindicated in women who are pregnant, have known or suspected pregnancy, or are breastfeeding. It should also be avoided by women over 35 who smoke, those with a history of thromboembolic disease, stroke, myocardial infarction, uncontrolled hypertension, active liver disease, or known hypersensitivity to any component of the ring.